Evenamide

Edit links
Source: Wikipedia, the free encyclopedia.
Evenamide
Clinical data
Other namesNW-3509; NW-3509A
Routes of
administration		oral
ATC code
  • None
Identifiers
  • 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
JSmol)
  • CCCCOc1cccc(CCNCC(=O)N(C)C)c1
  • InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
  • Key:GRHBODILPPXVKN-UHFFFAOYSA-N

Evenamide (

animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[5]

In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023.[6]


See also

References

  1. S2CID 8513976
    .
  2. ISBN 978-0-12-381293-3
    .
  3. ^
    ISBN 978-3-642-19922-6
    .
  4. ISBN 978-3-642-19921-9
    .
  5. ^ "Newron raised new funds to continue the development of Neurological therapies". Labiotech. 5 February 2015. Archived from the original on 4 March 2016.
  6. ^ "Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)". Newron Pharmaceuticals. 2024-01-04. Retrieved 2024-01-04.

External links